CRISPR Therapeutics to Participate in Upcoming Investor Conferences
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in June 2025. The company's senior management will present at William Blair's 45th Annual Growth Stock Conference on June 3 at 11:20 a.m. CT and at the Goldman Sachs' 46th Annual Global Healthcare Conference on June 9 at 3:20 p.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.
CRISPR Therapeutics (NASDAQ: CRSP), un'azienda biofarmaceutica specializzata in terapie geniche, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel giugno 2025. Il management senior dell'azienda presenterà al 45° Annual Growth Stock Conference di William Blair il 3 giugno alle 11:20 CT e al 46° Annual Global Healthcare Conference di Goldman Sachs il 9 giugno alle 15:20 ET. Le dirette streaming saranno disponibili sul sito web dell'azienda, con le registrazioni accessibili per 14 giorni dopo le presentazioni.
CRISPR Therapeutics (NASDAQ: CRSP), una compañía biofarmacéutica especializada en medicinas basadas en genes, ha anunciado su participación en dos importantes conferencias para inversores en junio de 2025. La alta dirección de la empresa presentará en la 45ª Conferencia Anual de Acciones de Crecimiento de William Blair el 3 de junio a las 11:20 a.m. CT y en la 46ª Conferencia Anual Global de Salud de Goldman Sachs el 9 de junio a las 3:20 p.m. ET. Las transmisiones en vivo estarán disponibles en el sitio web de la empresa, con repeticiones accesibles durante 14 días después de las presentaciones.
CRISPR Therapeutics (NASDAQ: CRSP)는 유전자 기반 의약품을 전문으로 하는 생명공학 회사로, 2025년 6월 두 개의 주요 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사의 고위 경영진은 6월 3일 오전 11시 20분 CT에 William Blair의 제45회 연례 성장주 컨퍼런스와 6월 9일 오후 3시 20분 ET에 Goldman Sachs의 제46회 연례 글로벌 헬스케어 컨퍼런스에서 발표할 예정입니다. 생중계는 회사 웹사이트에서 제공되며, 발표 후 14일간 다시보기 서비스를 이용할 수 있습니다.
CRISPR Therapeutics (NASDAQ : CRSP), une société biopharmaceutique spécialisée dans les médicaments à base de gènes, a annoncé sa participation à deux grandes conférences pour investisseurs en juin 2025. La direction de l'entreprise présentera lors de la 45e conférence annuelle Growth Stock de William Blair le 3 juin à 11h20 CT et lors de la 46e conférence annuelle mondiale sur la santé de Goldman Sachs le 9 juin à 15h20 ET. Des webdiffusions en direct seront disponibles sur le site de la société, avec des rediffusions accessibles pendant 14 jours après les présentations.
CRISPR Therapeutics (NASDAQ: CRSP), ein biopharmazeutisches Unternehmen, das sich auf genbasierte Medikamente spezialisiert hat, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Juni 2025 angekündigt. Das obere Management des Unternehmens wird am 45. jährlichen Growth Stock Conference von William Blair am 3. Juni um 11:20 Uhr CT und am 46. jährlichen Global Healthcare Conference von Goldman Sachs am 9. Juni um 15:20 Uhr ET präsentieren. Live-Webcasts sind auf der Unternehmenswebsite verfügbar, mit Wiederholungen, die 14 Tage nach den Präsentationen abrufbar sind.
- None.
- None.
ZUG, Switzerland and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences in June.
William Blair’s 45th Annual Growth Stock Conference
Date: Tuesday, June 3, 2025
Time: 11:20 a.m. CT
Goldman Sachs’ 46th Annual Global Healthcare Conference
Date: Monday, June 9, 2025
Time: 3:20 p.m. ET
A live webcast will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcasts will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has evolved from a research-stage company advancing gene editing programs into a leader that celebrated the historic approval of the first-ever CRISPR-based therapy. The Company has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. In 2018, CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease and transfusion-dependent beta thalassemia. Beginning in late 2023, CASGEVY® (exagamglogene autotemcel [exa-cel]) was approved in several countries to treat eligible patients with either of these conditions. The Nobel Prize-winning CRISPR technology has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has formed strategic partnerships with leading companies including Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California. To learn more, visit www.crisprtx.com.
Investor Contact:
+1-617-307-7503
ir@crisprtx.com
Media Contact:
+1-617-315-4493
media@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the William Blair Conference in 2025?
What investor conferences is CRISPR Therapeutics (CRSP) attending in June 2025?
How long will CRISPR Therapeutics' (CRSP) conference webcasts be available for replay?
Where can I watch CRISPR Therapeutics' (CRSP) investor conference presentations?
